Take a look at our previous reports:
Annual Report
2022
View Report
H1 Report
2023
View Report
Annual Report
2021
View Report
H1 Report
2022
View Report
Annual Report 2023
Twitter
LinkedIn
en
English
Dutch
Hauptmenü
change report
English
Dutch
Home
Our Business
Video message from the CEO and Chairman
Our Company
Our Vision and Mission
Our
Forward, Faster
Strategy
Key achievements in 2023
Corporate and Operational Performance
Financial Performance
The Galapagos shares in 2023
Outlook 2024
Going concern statement
Risk management and internal control
Disclaimer and other information
Portfolio
Patient stories
Portfolio
Oncology
CAR-T Pipeline manufactured at or near the point-of-care
GLPG5101: CD19 CAR-T in rrNHL
GLPG5201: CD19 CAR-T in rrCLL
GLPG5301: BCMA CAR-T in rrMM
Immunology
Small molecules pipeline
Jyseleca® franchise
TYK2 program: GLPG3667
Risk factors
Detailed description of the risk factors in Form 20-F
Product development and regulatory approval
Commercialization
Financial position and need for additional capital
Reliance on third parties
Intellectual property
Competitive position
Organization, structure and operation
Galapagos shares
General statement
Sustainability report
Our Sustainability Commitment
Our Ambition
Our Sustainability Governance
Our Double Materiality Assessment
Our Pillars
Patients
Our People
Planet
Trust & transparency
Reporting
Reporting framework
Advancing UN SDGs
Reporting on EU Taxonomy
Appendix
Energy Consumption
Greenhouse Gas Emissions
EU Taxonomy
Corporate governance
Governance policy
Board of Directors
Committees
Executive Committee
Share capital and shares
Shareholders
Remuneration Policy
Remuneration Report
Introduction
Board of Directors
Executive Committee
Equity components of the remuneration
Evolution of remuneration
Pay-ratio
Minimum share ownership
Contractual provisions regarding compensation for severance for Executive Committee members
Severance payments
Claw-back and malus
Deviations from the Remuneration Policy
Conflict of interests and related parties
Code of Conduct
Statement by the Board of Directors
Financial statements
Consolidated financial statements
Statements of income and comprehensive income/loss (-)
Statements of financial position
Cash flow statements
Statements of changes in equity
Notes to the consolidated financial statements
Notes 1-10
1.
General information
2.
Summary of significant transactions
3.
Material accounting policies
4.
Critical accounting judgments and key sources of estimation uncertainty
5.
Discontinued operations and assets held for sale
6.
Segment information
7.
Total net revenues from our continuing operations
8.
Operating costs and other operating income
9.
Staff costs
10.
Fair value adjustments, net currency exchange differences and other financial income/expenses
Notes 11-20
11.
Income taxes
12.
Earnings/loss (–) per share
13.
Goodwill and impairment of goodwill
14.
Intangible assets other than goodwill
15.
Property, plant and equipment
16.
Other non-current assets
17.
Research and development incentives receivables
18.
Inventories
19.
Trade and other receivables and other current assets
20.
Current financial investments
Notes 21-30
21.
Cash and cash equivalents
22.
Share capital
23.
Deferred tax
24.
Lease liabilities
25.
Trade and other liabilities and other non-current liabilities
26.
Deferred income
27.
Business combinations during the prior period
28.
Details of the NovAlix transaction
29.
Note to the cash flow statement
30.
Off-balance sheet arrangements
Notes 31-36
31.
Share-based payments
32.
Related parties
33.
Consolidated companies as of 31 December 2023
34.
Financial risk management
35.
Statutory auditor’s remuneration
36.
Events after balance sheet date
Overview statutory results
Auditor's report
Report of the statutory auditor
Our Business
Video message from the CEO and Chairman
Our Company
Our Vision and Mission
Our
Forward, Faster
Strategy
Key achievements in 2023
Corporate and Operational Performance
Financial Performance
The Galapagos shares in 2023
Outlook 2024
Going concern statement
Risk management and internal control
Disclaimer and other information
Portfolio
Patient stories
Portfolio
Oncology
CAR-T Pipeline manufactured at or near the point-of-care
GLPG5101: CD19 CAR-T in rrNHL
GLPG5201: CD19 CAR-T in rrCLL
GLPG5301: BCMA CAR-T in rrMM
Immunology
Small molecules pipeline
Jyseleca® franchise
TYK2 program: GLPG3667
Risk factors
Detailed description of the risk factors in Form 20-F
Product development and regulatory approval
Commercialization
Financial position and need for additional capital
Reliance on third parties
Intellectual property
Competitive position
Organization, structure and operation
Galapagos shares
General statement
Sustainability report
Our Sustainability Commitment
Our Ambition
Our Sustainability Governance
Our Double Materiality Assessment
Our Pillars
Patients
Our People
Planet
Trust & transparency
Reporting
Reporting framework
Advancing UN SDGs
Reporting on EU Taxonomy
Appendix
Energy Consumption
Greenhouse Gas Emissions
EU Taxonomy
Corporate governance
Governance policy
Board of Directors
Committees
Executive Committee
Share capital and shares
Shareholders
Remuneration Policy
Remuneration Report
Introduction
Board of Directors
Executive Committee
Equity components of the remuneration
Evolution of remuneration
Pay-ratio
Minimum share ownership
Contractual provisions regarding compensation for severance for Executive Committee members
Severance payments
Claw-back and malus
Deviations from the Remuneration Policy
Conflict of interests and related parties
Code of Conduct
Statement by the Board of Directors
Financial statements
Consolidated financial statements
Statements of income and comprehensive income/loss (-)
Statements of financial position
Cash flow statements
Statements of changes in equity
Notes to the consolidated financial statements
Notes 1-10
1.
General information
2.
Summary of significant transactions
3.
Material accounting policies
4.
Critical accounting judgments and key sources of estimation uncertainty
5.
Discontinued operations and assets held for sale
6.
Segment information
7.
Total net revenues from our continuing operations
8.
Operating costs and other operating income
9.
Staff costs
10.
Fair value adjustments, net currency exchange differences and other financial income/expenses
Notes 11-20
11.
Income taxes
12.
Earnings/loss (–) per share
13.
Goodwill and impairment of goodwill
14.
Intangible assets other than goodwill
15.
Property, plant and equipment
16.
Other non-current assets
17.
Research and development incentives receivables
18.
Inventories
19.
Trade and other receivables and other current assets
20.
Current financial investments
Notes 21-30
21.
Cash and cash equivalents
22.
Share capital
23.
Deferred tax
24.
Lease liabilities
25.
Trade and other liabilities and other non-current liabilities
26.
Deferred income
27.
Business combinations during the prior period
28.
Details of the NovAlix transaction
29.
Note to the cash flow statement
30.
Off-balance sheet arrangements
Notes 31-36
31.
Share-based payments
32.
Related parties
33.
Consolidated companies as of 31 December 2023
34.
Financial risk management
35.
Statutory auditor’s remuneration
36.
Events after balance sheet date
Overview statutory results
Auditor's report
Report of the statutory auditor
Suche
Home
Home
Privacy policy
Privacy policy
Downloads
Financial Calendar
Glossary of terms
